IS2070B - Stöðugar interferónlyfjablöndur á vökvaformi - Google Patents

Stöðugar interferónlyfjablöndur á vökvaformi

Info

Publication number: IS2070B
Authority: IS; Iceland
Prior art keywords: liquid; interferon; compositions; beta; continuous liquid
Prior art date: 1996-12-24

Application number

IS5087A

Other languages

English (en)

Other versions

IS5087A (is

Inventor

Mary D Dibiasi

Staples Mark

Chung Wen-Li

Scharin Eric

Original Assignee

Biogen Ides Ma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-24

Filing date

1999-06-21

Publication date

2005-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2070(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-06-21 Application filed by Biogen Ides Ma Inc filed Critical Biogen Ides Ma Inc

1999-06-21 Publication of IS5087A publication Critical patent/IS5087A/is

2005-12-15 Publication of IS2070B publication Critical patent/IS2070B/is

Links

239000007788 liquid Substances 0.000 title abstract 7
102000014150 Interferons Human genes 0.000 title abstract 4
108010050904 Interferons Proteins 0.000 title abstract 4
229940079322 interferon Drugs 0.000 title abstract 4
238000002360 preparation method Methods 0.000 title 1
239000000203 mixture Substances 0.000 abstract 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
102000003996 Interferon-beta Human genes 0.000 abstract 2
108090000467 Interferon-beta Proteins 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
229960001388 interferon-beta Drugs 0.000 abstract 2
239000004475 Arginine Substances 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
230000002378 acidificating effect Effects 0.000 abstract 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000001179 sorption measurement Methods 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Virology (AREA)
Oncology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IS5087A 1996-12-24 1999-06-21 Stöðugar interferónlyfjablöndur á vökvaformi IS2070B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3435396P	1996-12-24	1996-12-24
PCT/US1997/023817 WO1998028007A1 (en)	1996-12-24	1997-12-23	Stable liquid interferon formulations

Publications (2)

Publication Number	Publication Date
IS5087A IS5087A (is)	1999-06-21
IS2070B true IS2070B (is)	2005-12-15

Family

ID=21875893

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS5087A IS2070B (is)	1996-12-24	1999-06-21	Stöðugar interferónlyfjablöndur á vökvaformi

Country Status (27)

Country	Link
EP (1)	EP0948358B2 (is)
JP (5)	JP4878664B2 (is)
KR (2)	KR101042660B1 (is)
CN (2)	CN1222315C (is)
AT (1)	ATE270899T1 (is)
AU (1)	AU738362B2 (is)
BG (2)	BG65418B1 (is)
BR (1)	BR9714434A (is)
CA (1)	CA2275890C (is)
CZ (1)	CZ300636B6 (is)
DE (1)	DE69729880T3 (is)
DK (1)	DK0948358T4 (is)
EA (1)	EA002754B1 (is)
EE (2)	EE04266B1 (is)
ES (1)	ES2224290T5 (is)
HU (1)	HU224222B1 (is)
IL (1)	IL130524A (is)
IS (1)	IS2070B (is)
MX (1)	MX337876B (is)
NO (1)	NO327844B1 (is)
NZ (2)	NZ336548A (is)
PL (1)	PL193447B1 (is)
PT (1)	PT948358E (is)
SI (1)	SI0948358T2 (is)
SK (1)	SK284989B6 (is)
TR (1)	TR199901968T2 (is)
WO (1)	WO1998028007A1 (is)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030190307A1 (en)	1996-12-24	2003-10-09	Biogen, Inc.	Stable liquid interferon formulations
KR101042660B1 (ko) *	1996-12-24	2011-06-20	바이오겐 아이덱 엠에이 인코포레이티드	안정한 액체 인터페론 제제
DE59805732D1 (de)	1997-09-23	2002-10-31	Rentschler Biotech Gmbh	Flüssige interferon-beta-formulierungen
CN100448482C (zh) *	1999-05-31	2009-01-07	三菱化学株式会社	Hgf冻干制剂
US6887462B2 (en) *	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
UY27373A1 (es) *	2001-07-09	2003-02-28	Schering Ag	Formulaciones de interferón beta-humano
ES2325653T3 (es)	2001-12-21	2009-09-11	Novo Nordisk Health Care Ag	Composicion liquida de polipeptidos del factor vii.
US20060083733A1 (en) *	2002-01-18	2006-04-20	Fumihide Nishio	High-concentration preparation of soluble thrombomodulin
CA2490342C (en)	2002-06-21	2015-06-16	Novo Nordisk A/S	Stabilised solid compositions of factor vii polypeptides
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en)	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
TWI272948B (en)	2003-05-01	2007-02-11	Ares Trading Sa	HSA-free stabilized interferon liquid formulations
AR044302A1 (es) *	2003-05-13	2005-09-07	Ares Trading Sa	Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
BRPI0409936A (pt)	2003-05-23	2006-04-25	Novo Nordisk Healthcare Ag	uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
CN1318087C (zh) *	2003-06-06	2007-05-30	北京三诺佳邑生物技术有限责任公司	去白蛋白神经生长因子制剂
WO2005016365A2 (en)	2003-08-14	2005-02-24	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical composition of factor vii polypeptides
WO2005051456A2 (en) *	2003-11-13	2005-06-09	Alza Corporation	Composition and apparatus for transdermal delivery
EP1532983A1 (en)	2003-11-18	2005-05-25	ZLB Bioplasma AG	Immunoglobulin preparations having increased stability
ES2676644T3 (es)	2003-12-19	2018-07-23	Novo Nordisk Health Care Ag	Composiciones estabilizadas de polipéptidos de factor VII
BRPI0510527A (pt) *	2004-06-01	2007-10-30	Ares Trading Sa	método de estabilização de proteìnas
ES2620326T3 (es) *	2004-08-24	2017-06-28	Kangawa, Kenji	Preparación líquida de péptido fisiológicamente activo
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN101056890B (zh) *	2004-11-10	2012-05-09	诺华疫苗和诊断公司	脱酰胺基干扰素-β
BRPI0606658B8 (pt) *	2005-01-12	2021-05-25	Biogen Idec Inc	método para armazenar e distribuir interferon-beta, e dispositivo
EP1838290A2 (en) *	2005-01-21	2007-10-03	Alza Corporation	Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
DK1899462T3 (da)	2005-07-02	2011-06-06	Arecor Ltd	Stabile vandige systemer omfattende proteiner
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
MX2008014024A (es)	2006-05-04	2008-11-14	Boehringer Ingelheim Int	Formas poliformas.
CN101932308B (zh) *	2007-12-04	2014-11-05	治疗医药股份有限公司	改良的配制剂和用于冻干的方法及由此提供的冻干物
ES2387236T3 (es)	2007-12-20	2012-09-18	Merck Serono S.A.	Formulaciones de interferón beta pegilado
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
ES2519475T5 (es)	2008-05-01	2018-07-02	Arecor Limited	Formulación de una proteína
EP2328607A1 (en)	2008-07-16	2011-06-08	Arecor Limited	Stable formulation of a therapeutic protein
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh)	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
DE102008051574A1 (de)	2008-10-14	2010-04-15	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh)	2008-12-23	2017-08-04	勃林格殷格翰国际有限公司	有机化合物的盐形式
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
DE102009032179A1 (de)	2009-07-07	2011-01-13	Biogenerix Ag	Verfahren zur Reinigung von Interferon beta
EP2504002B1 (en)	2009-11-27	2019-10-09	Boehringer Ingelheim International GmbH	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CA2788863C (en)	2010-02-04	2020-07-07	Csl Behring Ag	Immunoglobulin preparation
EP2361636A1 (en)	2010-02-26	2011-08-31	CSL Behring AG	Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) *	2010-03-15	2011-09-15	Kurt Koch	Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
KR101927068B1 (ko)	2010-05-05	2018-12-10	베링거 인겔하임 인터내셔날 게엠베하	체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20200028498A (ko)	2010-06-24	2020-03-16	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2649993B1 (en) *	2010-12-09	2017-04-05	Maruishi Pharmaceutical Co., Ltd.	Stabilizer of acetaminophen
SMT201800221T1 (it)	2011-03-15	2018-07-17	Biogen Ma Inc	Metodo per ridurre i sintomi simil-influenzali associati alla somministrazione intramuscolare di interferone utilizzando un regime di dosaggio crescente a titolazione rapida
HUE061596T2 (hu)	2011-07-15	2023-07-28	Boehringer Ingelheim Int	Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP2015515480A (ja) *	2012-04-19	2015-05-28	シー・アール・バード・インコーポレーテッドＣＲＢａｒｄＩｎｃｏｒｐｏｒａｔｅｄ	エチレンオキシド滅菌下のｐＨ安定性が改善された注入液
ES2929025T3 (es)	2012-05-14	2022-11-24	Boehringer Ingelheim Int	Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
US20130303462A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it)	2012-05-28	2013-11-29	Nicoletta Maxia	Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) *	2013-03-07	2014-11-05	安徽安科生物工程（集团）股份有限公司	一种重组人干扰素α2b制剂
EP3110449B1 (en)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medical use of a dpp-4 inhibitor
JP2014208669A (ja) *	2014-06-17	2014-11-06	株式会社スリー・ディー・マトリックス	タンパク質の凝集抑制剤
MX388043B (es)	2014-12-03	2025-03-19	Csl Behring Ag	Producto farmacéutico con estabilidad incrementada que comprende inmunoglobulinas.
BR112018072401A2 (pt)	2016-06-10	2019-02-19	Boehringer Ingelheim International Gmbh	combinações de linagliptina e metformina
KR101943160B1 (ko) *	2016-10-06	2019-01-30	에이비온 주식회사	인터페론 베타 변이체의 안정화 제제
EP4233901A3 (en)	2017-08-22	2023-09-06	Biogen MA Inc.	Pharmaceutical compositions containing anti-beta amyloid antibodies
KR102731889B1 (ko) *	2019-07-18	2024-11-19	에이비온 주식회사	2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) *	2019-11-20	2023-04-07	迈克生物股份有限公司	蛋白c活性测定试剂盒
JP2023524248A (ja) *	2020-04-29	2023-06-09	アビオンインク．	二重突然変異を有するヒトインターフェロン－ベータ変異体及びヒトインターフェロン－ベータ変異体の安全性を向上させる方法
EP4400432A3 (en) *	2021-03-30	2024-09-18	SCHOTT Pharma Schweiz AG	System for low-temperature storage of a pharmaceutical composi-tion, liquid composition, method and uses
CN114177273B (zh) *	2021-11-29	2024-05-28	苏州人本药业有限公司	一种含有神经毒素的液体制剂及其制备方法
EP4456900A4 (en) *	2021-12-27	2025-12-24	Enalare Therapeutics Inc	RESPIRATORY STIMULATING PARENTERAL FORMULATIONS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57175125A (en) *	1981-04-20	1982-10-28	Wakunaga Yakuhin Kk	Preparation of beta-interferon
EP0082481B2 (en) *	1981-12-23	1990-09-12	Schering Corporation	Stabilised alpha-interferon formulations and their preparation
JPS60243028A (ja) *	1984-04-28	1985-12-03	Kyowa Hakko Kogyo Co Ltd	インタ−フエロンの可溶化方法
JPS63196268A (ja) *	1987-02-10	1988-08-15	Kanegafuchi Chem Ind Co Ltd	無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) *	1987-03-13	1988-09-28	Interferon Sciences, Inc.	Lyophilized lymphokine composition
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
US4895716A (en) *	1987-06-09	1990-01-23	Biogen, Inc.	Stabilized formulations of gamma interferons
JPH02124832A (ja) *	1988-07-08	1990-05-14	Toray Ind Inc	インターヘェロンβ組成物
DE3939346A1 (de) *	1989-11-29	1991-06-06	Behringwerke Ag	Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) *	1993-05-12	2001-01-28	Genentech Inc	Stable liquid compositions of gamma interferon
TW249202B (is) *	1993-08-13	1995-06-11	Ciba Gerigy Corp
US5545723A (en) *	1994-03-15	1996-08-13	Biogen Inc.	Muteins of IFN-β
EP0752880A4 (en) *	1994-04-08	2000-08-09	Brigham & Womens Hospital	TREATMENT OF AUTOIMMUNE DISEASES BY ORAL TOLERATION AND / OR INTERFERON OF TYPE I
IT1272252B (it) *	1994-05-16	1997-06-16	Applied Research Systems	Formulazioni liquide di interferone beta
TW426523B (en) *	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
KR101042660B1 (ko) *	1996-12-24	2011-06-20	바이오겐 아이덱 엠에이 인코포레이티드	안정한 액체 인터페론 제제

1997
- 1997-12-23 KR KR1020077010020A patent/KR101042660B1/ko not_active Expired - Lifetime
- 1997-12-23 PL PL97334365A patent/PL193447B1/pl unknown
- 1997-12-23 ES ES97952621T patent/ES2224290T5/es not_active Expired - Lifetime
- 1997-12-23 SK SK858-99A patent/SK284989B6/sk not_active IP Right Cessation
- 1997-12-23 SI SI9730670T patent/SI0948358T2/sl unknown
- 1997-12-23 WO PCT/US1997/023817 patent/WO1998028007A1/en not_active Ceased
- 1997-12-23 DK DK97952621.7T patent/DK0948358T4/da active
- 1997-12-23 AT AT97952621T patent/ATE270899T1/de active
- 1997-12-23 HU HU0000829A patent/HU224222B1/hu active IP Right Grant
- 1997-12-23 CZ CZ0228299A patent/CZ300636B6/cs not_active IP Right Cessation
- 1997-12-23 TR TR1999/01968T patent/TR199901968T2/xx unknown
- 1997-12-23 JP JP52905698A patent/JP4878664B2/ja not_active Expired - Fee Related
- 1997-12-23 NZ NZ336548A patent/NZ336548A/en not_active IP Right Cessation
- 1997-12-23 IL IL13052497A patent/IL130524A/xx not_active IP Right Cessation
- 1997-12-23 PT PT97952621T patent/PT948358E/pt unknown
- 1997-12-23 CA CA2275890A patent/CA2275890C/en not_active Expired - Lifetime
- 1997-12-23 AU AU56191/98A patent/AU738362B2/en not_active Expired
- 1997-12-23 EE EEP200300127A patent/EE04266B1/xx unknown
- 1997-12-23 EP EP97952621A patent/EP0948358B2/en not_active Expired - Lifetime
- 1997-12-23 EE EEP199900313A patent/EE04223B1/xx unknown
- 1997-12-23 DE DE69729880T patent/DE69729880T3/de not_active Expired - Lifetime
- 1997-12-23 BR BR9714434-7A patent/BR9714434A/pt active Search and Examination
- 1997-12-23 EA EA199900597A patent/EA002754B1/ru not_active IP Right Cessation
- 1997-12-23 CN CNB971814996A patent/CN1222315C/zh not_active Expired - Lifetime
- 1997-12-23 CN CN2005100915177A patent/CN1733296B/zh not_active Expired - Lifetime
- 1997-12-23 KR KR1019997005701A patent/KR20000069664A/ko not_active Ceased
1999
- 1999-06-21 IS IS5087A patent/IS2070B/is unknown
- 1999-06-23 NO NO993121A patent/NO327844B1/no not_active IP Right Cessation
- 1999-06-23 MX MX2012000515A patent/MX337876B/es unknown
- 1999-07-19 BG BG109523A patent/BG65418B1/bg unknown
- 1999-07-19 BG BG103594A patent/BG65171B1/bg unknown
2001
- 2001-07-05 NZ NZ512792A patent/NZ512792A/xx not_active IP Right Cessation
2007
- 2007-05-18 JP JP2007133540A patent/JP2007204501A/ja not_active Withdrawn
2011
- 2011-01-07 JP JP2011002557A patent/JP5851695B2/ja not_active Expired - Lifetime
- 2011-10-04 JP JP2011220534A patent/JP2012006979A/ja not_active Withdrawn
2014
- 2014-02-25 JP JP2014033581A patent/JP2014098029A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE69729880T3 (de)	2012-05-10
HK1092048A1 (zh)	2007-02-02
JP4878664B2 (ja)	2012-02-15
EE9900313A (et)	2000-04-17
DK0948358T3 (da)	2004-11-08
IL130524A0 (en)	2000-06-01
EE04223B1 (et)	2004-02-16
DK0948358T4 (da)	2012-03-19
EA002754B1 (ru)	2002-08-29
BR9714434A (pt)	2000-05-02
HUP0000829A3 (en)	2002-01-28
SI0948358T1 (en)	2005-04-30
JP2011068694A (ja)	2011-04-07
MX337876B (es)	2016-03-22
IS5087A (is)	1999-06-21
DE69729880T2 (de)	2005-07-07
JP2007204501A (ja)	2007-08-16
HU224222B1 (hu)	2005-06-28
BG65171B1 (bg)	2007-05-31
KR20000069664A (ko)	2000-11-25
NO993121L (no)	1999-08-24
CN1222315C (zh)	2005-10-12
EP0948358B1 (en)	2004-07-14
ATE270899T1 (de)	2004-07-15
CN1245434A (zh)	2000-02-23
ES2224290T3 (es)	2005-03-01
DE69729880D1 (de)	2004-08-19
CN1733296A (zh)	2006-02-15
BG65418B1 (bg)	2008-07-31
NO327844B1 (no)	2009-10-05
SK284989B6 (sk)	2006-04-06
JP5851695B2 (ja)	2016-02-03
KR101042660B1 (ko)	2011-06-20
CA2275890C (en)	2011-11-01
CA2275890A1 (en)	1998-07-02
HUP0000829A2 (en)	2000-07-28
WO1998028007A1 (en)	1998-07-02
AU5619198A (en)	1998-07-17
CZ300636B6 (cs)	2009-07-08
EP0948358B2 (en)	2011-11-23
SK85899A3 (en)	2000-01-18
NZ336548A (en)	2001-09-28
NO993121D0 (no)	1999-06-23
IL130524A (en)	2005-08-31
KR20070052363A (ko)	2007-05-21
EE200300127A (et)	2003-06-16
BG109523A (en)	2007-05-31
PL334365A1 (en)	2000-02-28
EP0948358A1 (en)	1999-10-13
AU738362B2 (en)	2001-09-13
ES2224290T5 (es)	2012-03-12
EE04266B1 (et)	2004-04-15
PL193447B1 (pl)	2007-02-28
SI0948358T2 (sl)	2012-03-30
HK1025040A1 (en)	2000-11-03
EA199900597A1 (ru)	2000-02-28
BG103594A (en)	2000-04-28
JP2001519770A (ja)	2001-10-23
TR199901968T2 (xx)	1999-12-21
NZ512792A (en)	2002-11-26
CN1733296B (zh)	2010-05-26
CZ228299A3 (cs)	1999-12-15
JP2014098029A (ja)	2014-05-29
JP2012006979A (ja)	2012-01-12
PT948358E (pt)	2004-10-29

Publication	Publication Date	Title
IS2070B (is)	2005-12-15	Stöðugar interferónlyfjablöndur á vökvaformi
CA2113995A1 (en)	1993-03-18	Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
CA2032499A1 (en)	1991-01-21	Polypeptide derivatives
AU586892B2 (en)	1989-07-27	Pharmaceutical and dietary composition
DE3166150D1 (en)	1984-10-25	N-(vinblastinoyl-23) derivatives of amino acids and peptides and their preparation
EP1197220A3 (en)	2009-04-15	Therapeutic methods and compositions based on delta proteins and nucleic acids
AU1094892A (en)	1992-08-27	Improved activation of recombinant proteins
EP0827749A3 (en)	1998-04-22	Peritoneal dialysis solution
AU678421B2 (en)	1997-05-29	Highly concentrated TCF pharmaceutical preparations
AU3494093A (en)	1994-08-15	S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
EP0063328A3 (en)	1983-06-08	Compositions containing secretin and method for preventing the adsorption of secretin
EP0723016A3 (en)	1997-08-20	Leukocyte activation factor
CA2153071A1 (en)	1994-07-21	Derivatized calcitonins
NZ509773A (en)	2002-10-25	Casein formulations for the delivery of bioactive constituents